Alzheimer’s Drug Discovery Program: Core Requests for Proposals (multiple opportunities)

The ADDF offers funding to researchers for Alzheimer’s drug discovery, clinical trials, and biomarker development research. Core request for proposals include:

Program to Accelerate Clinical Trials (PACT)
Amount: Up to $3 Million
The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

Neuroimaging and CSF Biomarker Development
Amount: Up to $600,000
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Prevention Pipeline
Amount: Up to $3 Million
The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Drug Development
Amount: Up to $600,000
The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

Please contact Lynn Wong if you are interested in applying to this opportunity.